Morschhauser F, Fowler NH, Feugier P, et al. RELEVANCE: phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma. EHA 2018; abstract S154.
Grote verschillen tussen landen in toegang tot nieuwe medicatie
mrt 2024 | Borstkanker, Dermato-oncologie, Gynaecologische oncologie, Leukemie, Longoncologie, Uro-oncologie